List of Excipients in Branded Drug GATIFLOXACIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pacific Pharma Inc	GATIFLOXACIN	gatifloxacin	60758-615	BENZALKONIUM CHLORIDE
Pacific Pharma Inc	GATIFLOXACIN	gatifloxacin	60758-615	EDETATE DISODIUM
Pacific Pharma Inc	GATIFLOXACIN	gatifloxacin	60758-615	HYDROCHLORIC ACID

Generic Drugs Containing GATIFLOXACIN

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	gatifloxacin	0378-5431	BENZALKONIUM CHLORIDE
Mylan Pharmaceuticals Inc	gatifloxacin	0378-5431	EDETATE DISODIUM
Mylan Pharmaceuticals Inc	gatifloxacin	0378-5431	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in GATIFLOXACIN?

# Of NDCs	Excipient
7	BENZALKONIUM CHLORIDE
7	EDETATE DISODIUM
7	HYDROCHLORIC ACID

Gatifloxacin Excipient Strategy and Commercial Opportunities

Last updated: October 26, 2026

Gatifloxacin is a mature fluoroquinolone with limited U.S. systemic commercial potential because oral and injectable products were withdrawn after safety concerns involving dysglycemia. The strongest remaining opportunity is ophthalmic gatifloxacin, particularly preservative-free unit-dose products, multidose preservative systems, pediatric formulations, and differentiated products for markets where generic fluoroquinolone demand remains high.

Excipient selection should focus on ocular tolerability, chemical stability, preservative performance, container compatibility, manufacturing cost, and regulatory differentiation. The active ingredient is no longer protected by a commercially meaningful primary patent estate in major markets, so product value depends mainly on formulation execution, regulatory positioning, manufacturing reliability, and distribution.

What is the current FDA status of gatifloxacin?

Gatifloxacin has different regulatory positions depending on the dosage form.

Product type	Historical product	Primary use	Current commercial position
Oral tablets	Tequin	Systemic bacterial infections	Withdrawn from the U.S. market
Intravenous injection	Tequin IV	Systemic bacterial infections	Withdrawn from the U.S. market
Ophthalmic solution	Zymar, Zymaxid	Bacterial conjunctivitis and ocular infections	Generic and branded ophthalmic products remain commercially relevant in selected markets
Ophthalmic formulations under development	Various generic and specialty products	Conjunctivitis, post-operative ocular infection	Potentially viable where differentiated by preservation, packaging, or supply

Bristol-Myers Squibb discontinued Tequin in the United States in 2006 after reports of serious blood-glucose disturbances, including hypoglycemia and hyperglycemia. FDA determined that the risks associated with systemic gatifloxacin outweighed its benefits for the relevant patient population.[1]

Ophthalmic gatifloxacin has a different risk profile because systemic exposure is substantially lower than with oral or intravenous administration. FDA approved Zymar ophthalmic solution, containing gatifloxacin 0.3%, in 2003. Zymaxid ophthalmic solution, containing gatifloxacin 0.5%, was approved in 2010 for bacterial conjunctivitis.[2,3]

What excipients are used in gatifloxacin ophthalmic products?

Commercial ophthalmic gatifloxacin products generally use a simple aqueous formulation. The main formulation functions are pH control, tonicity adjustment, chelation, preservation, and viscosity management.

Historical branded gatifloxacin ophthalmic products used combinations that included:

• Gatifloxacin at 0.3% or 0.5%
• Benzalkonium chloride as a preservative
• Glycerin for tonicity adjustment
• Disodium edetate as a chelating agent
• Hydrochloric acid or sodium hydroxide for pH adjustment
• Purified water as the vehicle

The precise qualitative and quantitative composition varies by product and manufacturer. Approved labeling should control any product-specific assessment.[2,3]

What does each excipient contribute?

Excipient category	Typical function	Commercial relevance
Benzalkonium chloride	Antimicrobial preservation	Low cost and established regulatory history, but may cause ocular-surface irritation with repeated use
Glycerin	Tonicity adjustment and comfort support	Simple, inexpensive, and compatible with aqueous ophthalmic products
Disodium edetate	Chelation and preservative support	Can improve preservative performance and reduce metal-catalyzed degradation
Hydrochloric acid and sodium hydroxide	pH adjustment	Required for final product optimization and stability
Purified water	Vehicle	Standard aqueous ophthalmic carrier
Hydroxypropyl methylcellulose or similar polymer	Viscosity enhancement	May improve residence time but can affect drop size, comfort, and filtration
Borate or phosphate buffer systems	pH control	Can improve stability but require careful ocular-tolerance and regulatory assessment
Alternative preservatives	Microbial protection	May support differentiation but can increase development and qualification costs

How should a gatifloxacin excipient strategy be designed?

The highest-value strategy is to develop separate formulation platforms rather than one universal product.

Platform 1: Low-cost preserved ophthalmic solution

A conventional multidose bottle using benzalkonium chloride offers the lowest development and manufacturing cost. This platform is appropriate for price-sensitive generic markets and institutional procurement.

The formulation priorities are:

1. Demonstrated antimicrobial effectiveness.
2. Chemical stability through the labeled shelf life.
3. Compatibility with the bottle, cap, dropper, and seal.
4. Acceptable ocular comfort.
5. Low viscosity to support reliable drop formation.
6. Robust sterile filtration and aseptic filling.

A conventional preserved product is unlikely to command a substantial price premium. Its commercial advantage would come from supply continuity, lower cost of goods, regional registration, or reliable hospital distribution.

Platform 2: Preservative-free unit-dose vials

Preservative-free gatifloxacin is the clearest formulation-led opportunity. It would target patients with ocular-surface disease, frequent dosing, contact-lens-related sensitivity, post-operative care, and repeated exposure to topical ophthalmic products.

The main benefits are reduced exposure to benzalkonium chloride and improved suitability for patients who cannot tolerate preserved drops. The principal disadvantages are higher packaging costs, greater unit-dose filling complexity, increased packaging volume, and more demanding supply-chain management.

A preservative-free product could use:

• Blow-fill-seal plastic ampoules
• Low-density polyethylene unit-dose containers
• Sterile single-use vials
• Multidose preservative-free delivery systems, if technically and commercially justified

The formulation must address extractables and leachables, oxygen and moisture ingress, container closure integrity, dose uniformity, and microbial protection after opening. A preservative-free label requires a packaging system that prevents contamination rather than relying on the formulation to control it.

Platform 3: Low-preservative or alternative-preservative multidose product

A multidose bottle using a lower-irritancy preservative could occupy a middle position between standard benzalkonium chloride products and preservative-free packaging.

Potential systems may include polyquaternium-based preservatives, oxidative preservatives, or other ophthalmic antimicrobial systems. Each system creates a separate regulatory and compatibility package. The key risk is that a preservative with better tolerability may have weaker formulation precedent, higher analytical burden, or unfavorable interaction with the active ingredient and container.

This route is commercially attractive only if the product can show a clear tolerability or usage advantage. A modest change in preservative without a clinically meaningful benefit may not support premium pricing.

What formulations are protected by gatifloxacin patents?

The original composition-of-matter and core product patents for gatifloxacin are legacy rights in most major markets. Commercial protection is therefore more likely to arise from formulation patents, manufacturing processes, packaging systems, or specific therapeutic uses than from the active molecule itself.

Potentially protectable subject matter includes:

• Preservative-free gatifloxacin ophthalmic compositions
• Narrow pH and osmolality ranges
• Improved chemical-stability systems
• Multidose sterile delivery devices
• Low-irritancy preservative combinations
• High-concentration gatifloxacin ophthalmic solutions
• Sustained-release ocular inserts or in situ gels
• Combination products containing gatifloxacin and anti-inflammatory agents
• Manufacturing processes that reduce degradation or particulate formation
• Container-closure systems that improve sterility assurance

A formulation patent must provide more than a routine substitution of one excipient for another. Patent strength improves when the formulation demonstrates an unexpected stability, tolerability, preservative, delivery, or manufacturing result.

When does gatifloxacin lose exclusivity?

Gatifloxacin's principal U.S. systemic commercial exclusivity has already expired or become commercially irrelevant. The compound was discovered and commercialized before the current generic market structure for fluoroquinolones matured. The original systemic products faced generic competition before their U.S. withdrawal.

Ophthalmic gatifloxacin also has a mature generic profile. Any current exclusivity would most likely arise from a specific formulation, device, label, or regulatory designation rather than from the base active ingredient.

Exclusivity category	Gatifloxacin position
Compound patent	Legacy rights; no meaningful current global barrier expected
Oral formulation patents	Commercially expired or irrelevant in the U.S.
Injectable formulation patents	Commercially expired or irrelevant in the U.S.
Ophthalmic composition patents	Any surviving rights require product- and jurisdiction-specific review
Pediatric exclusivity	No current broad market exclusivity identified
Orphan exclusivity	Not applicable to ordinary gatifloxacin products
Biologic exclusivity	Not applicable
Regulatory exclusivity	Product-specific and generally not a major current barrier

Exact patent expiration dates must be verified against the relevant patent family, terminal disclaimers, patent-term adjustment, and country-specific registers. A generic development program should not assume that an expired compound patent eliminates all freedom-to-operate risk for a delivery device or combination product.

Is gatifloxacin listed in the Orange Book?

FDA Orange Book treatment depends on the product, applicant, dosage form, and marketing status. Historical branded ophthalmic products and generic equivalents may appear differently from discontinued systemic products. A current Orange Book review should distinguish:

• Active versus discontinued products
• Reference-listed drugs versus authorized generics
• Listed patents versus expired patents
• Drug-device listings
• Product-specific exclusivity codes
• Patent delisting or expiration status

For gatifloxacin, the practical commercial issue is unlikely to be a live core patent. The relevant diligence question is whether a proposed ophthalmic product implicates a listed formulation, device, or method-of-use patent associated with a currently marketed reference product.

Are Paragraph IV challenges relevant to gatifloxacin?

Paragraph IV litigation risk is generally low for mature gatifloxacin ophthalmic products because the main active-ingredient rights are old and generic competition is established. A Paragraph IV certification could still arise if a newer branded product has an unexpired formulation, delivery-device, or combination patent.

Potential Paragraph IV targets would include:

• Preservative-free gatifloxacin products
• Fixed-dose antibiotic-steroid combinations
• Sustained-release ocular delivery systems
• Novel multidose bottles
• New indications supported by method-of-use patents

For a standard 0.3% or 0.5% ophthalmic solution using conventional excipients, litigation exposure is more likely to involve product-specific formulation or device patents than the gatifloxacin molecule.

What generic entry risks exist for gatifloxacin?

Generic entry risk is high for conventional ophthalmic gatifloxacin products. The active ingredient is well known, the dosage form is technically familiar, and the clinical use is established.

The main barriers are operational rather than scientific:

• Sterile manufacturing capacity
• Process validation
• Container-closure integrity
• Preservative effectiveness testing
• Stability in the final container
• Supply of ophthalmic-grade packaging
• Regulatory approval in each target market
• Tender pricing and distributor access

A standard preserved product may face rapid price erosion. A differentiated product can reduce direct substitution risk, but the differentiation must be visible to prescribers, pharmacies, hospitals, or payers.

How strong is the patent estate for gatifloxacin?

The base patent estate is weak as a current commercial barrier. The stronger opportunities are narrow and formulation-specific.

IP category	Relative strength	Strategic assessment
Gatifloxacin compound	Low current value	Mature and widely known active ingredient
Standard ophthalmic solution	Low	Easy generic substitution
Preservative-free formulation	Moderate	Value depends on data and packaging claims
Multidose preservative-free device	Moderate to high	Device and sterility claims may create differentiation
Sustained-release ocular delivery	Moderate to high	Higher technical risk and longer development timeline
Combination antibiotic-steroid product	Moderate	Clinical positioning and patent scope are critical
Manufacturing process	Low to moderate	Stronger if process yields measurable quality or cost benefits

What commercial opportunities remain for gatifloxacin?

Preservative-free ophthalmic products

This is the most credible opportunity for differentiated development. The product could target ophthalmologists, optometrists, ambulatory surgery centers, and patients with ocular-surface sensitivity.

Commercial success would depend on:

• A credible tolerability advantage
• Convenient packaging
• Competitive pricing
• Reliable sterile supply
• Distribution through specialty ophthalmology channels

Emerging-market generic supply

Gatifloxacin remains commercially relevant in some countries despite its U.S. systemic withdrawal. Regional opportunities may exist for ophthalmic products, subject to local regulatory requirements and national treatment guidelines.

The strongest markets are likely to be those with:

• Established fluoroquinolone prescribing
• Local sterile ophthalmic manufacturing
• Hospital or pharmacy tender systems
• Price sensitivity favoring generic products
• Limited access to newer topical antibiotics

Systemic gatifloxacin requires greater regulatory caution because of the historical dysglycemia risk. Ophthalmic development is commercially and clinically more defensible.

Combination products

A gatifloxacin and corticosteroid combination may support a stronger commercial position in post-operative ocular care. The development burden is higher because the sponsor must establish compatibility, dose justification, safety, and appropriate labeling for both components.

Potential combinations could target:

• Post-cataract inflammation and infection
• Corneal surgery
• Ocular trauma
• Bacterial conjunctivitis with clinically relevant inflammation

The principal risks are steroid-related safety concerns, competition from established antibiotic-steroid products, and limited room for differentiation.

Enhanced-residence formulations

Increasing ocular residence time through mild viscosity enhancement, mucoadhesive polymers, gels, or in situ gelling systems could reduce dosing frequency. The technical challenge is preserving comfort, clarity, drop accuracy, and sterile manufacturability.

A higher-viscosity product may be unattractive if it causes blurred vision or inconsistent drop delivery. The commercial claim must be supported by pharmacokinetic, clinical, or adherence data.

Contract manufacturing and licensing

The most practical licensing opportunities may involve:

• A sterile ophthalmic manufacturing platform
• A preservative-free container system
• A regional marketing authorization
• A differentiated excipient package
• A combination-product development program
• Manufacturing rights in emerging markets

An owner of gatifloxacin know-how is more likely to monetize manufacturing, formulation, or distribution capabilities than a legacy compound patent.

How does gatifloxacin compare with competing ophthalmic antibiotics?

Product	Main advantage	Main commercial constraint
Gatifloxacin	Established fluoroquinolone; generic supply; familiar ophthalmic use	Limited differentiation and mature pricing
Moxifloxacin	Strong brand recognition and broad ophthalmic use	Intense generic competition
Ofloxacin	Low cost and long market history	Older molecule and lower premium potential
Besifloxacin	Ophthalmic-specific positioning	Higher cost and narrower market
Tobramycin	Established use and low-cost generic supply	Different spectrum and formulation positioning
Azithromycin ophthalmic	Less frequent dosing in some products	Higher cost and formulation-specific limitations

Gatifloxacin is most competitive when positioned as a reliable, low-cost ophthalmic fluoroquinolone or as a differentiated preservative-free product. It is less attractive as a premium conventional multidose solution without a clear clinical or tolerability advantage.

What manufacturing and IP barriers affect commercialization?

The key manufacturing barriers are sterile processing and packaging, not synthesis of the active ingredient.

A commercial program should assess:

• Active pharmaceutical ingredient impurity profile
• Particle control and dissolution
• pH-related degradation
• Light sensitivity
• Preservative adsorption to packaging
• Extractables and leachables
• Container-closure integrity
• Drop-size consistency
• Sterility assurance
• Filter compatibility
• Stability after opening
• Shipping under temperature stress

For preserved multidose bottles, preservative depletion and adsorption can create product-performance problems. For unit-dose products, packaging cost and filling throughput can determine profitability. For viscous or gel formulations, filtration and fill accuracy become more difficult.

What is the likely generic launch scenario?

The most likely launch path is a standard generic ophthalmic solution in a conventional multidose bottle. This route has the lowest technical and regulatory risk but also the highest price pressure.

A differentiated launch could follow three scenarios:

Scenario	Product	Commercial outcome
Low-cost generic	Preserved 0.3% or 0.5% solution	High substitution risk and rapid price competition
Specialty generic	Preservative-free unit-dose product	Higher packaging cost but potential premium
Platform product	Advanced delivery or combination formulation	Higher development cost and greater IP potential

A sponsor seeking defensible value should prioritize the specialty-generic or platform-product route rather than rely solely on a conventional gatifloxacin solution.

Key Takeaways

• Gatifloxacin's current commercial opportunity is concentrated in ophthalmic products.
• Systemic oral and injectable products have limited U.S. prospects because of the historical dysglycemia safety issue.
• The base gatifloxacin patent estate is not a meaningful current barrier in major markets.
• Conventional preserved ophthalmic solutions are technically straightforward but highly exposed to generic price competition.
• Preservative-free unit-dose packaging offers the clearest excipient-led differentiation.
• Alternative preservatives and viscosity-enhanced systems may create value, but only with measurable tolerability, stability, or dosing benefits.
• Combination antibiotic-steroid products and advanced ocular delivery systems offer greater IP potential but require substantially more clinical and regulatory work.
• The primary manufacturing barriers are sterile filling, packaging compatibility, preservative performance, and supply reliability.
• Licensing value is more likely to reside in formulation know-how, delivery systems, manufacturing capacity, or regional market access than in ownership of the gatifloxacin molecule.

FAQs

Can gatifloxacin be reformulated as a preservative-free eye drop?

Yes. A preservative-free product would require single-dose packaging or a validated multidose preservative-free delivery system. The development program must establish sterility, container-closure integrity, stability, dose uniformity, and usability.

Which excipient is most likely to limit chronic ophthalmic use?

Benzalkonium chloride is the main excipient-related concern because repeated exposure can aggravate ocular-surface irritation in susceptible patients. Its use remains common because it is effective, inexpensive, and well established.

Is a gatifloxacin suspension commercially attractive?

Usually less attractive than a solution because suspensions require redispersibility, particle-size control, dose uniformity, and shake-related labeling. A suspension may be justified only for a formulation or delivery benefit unavailable in a solution.

Can gatifloxacin be combined with dexamethasone?

A gatifloxacin-dexamethasone product is technically possible, but it would require compatibility, stability, safety, and clinical justification for the combination. The product would compete with existing antibiotic-steroid ophthalmic therapies.

Does gatifloxacin have biosimilar competition?

No. Gatifloxacin is a small-molecule drug, so competition occurs through conventional generic pathways rather than biosimilar regulation.

References

1. U.S. Food and Drug Administration. (2006). FDA patient safety information: Tequin (gatifloxacin) withdrawn from the U.S. market. FDA.

2. U.S. Food and Drug Administration. (2003). Zymar ophthalmic solution prescribing information. FDA.

3. U.S. Food and Drug Administration. (2010). Zymaxid ophthalmic solution prescribing information. FDA.

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

5. U.S. Food and Drug Administration. (2019). Container closure systems for packaging human drugs and biologics: Guidance for industry. FDA.